Navigation Links
30 percent RA patients refractory to anti-TNFs achieve disease remission with tocilizumab plus metho
Date:6/13/2008

Paris, France, Friday 13 June 2008: Tocilizumab plus methotrexate showed significant clinical improvements in efficacy and safety in patients with moderate to severe rheumatoid arthritis (RA), who had not adequately responded to anti-tumour necrosis factor (anti-TNF) therapy, according to a new study presented today at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France. Tocilizumab, an anti-interleukin (IL)-6 receptor monoclonal antibody, was demonstrated to be effective irrespective of the number of, or the most recently-failed anti-TNF treatments.

After 24 weeks of treatment, 30.1% (p<0.0001) of patients receiving 8mg/kg tocilizumab plus methotrexate, who had active RA despite prior anti-TNF therapy, achieved DAS28 (a measure of disease remission) compared with only 1.6% in the placebo arm. 50% (p<0.0001) of patients on the same regime achieved the study's primary endpoint of ACR20 (a 20% improvement in symptoms) compared to 10% of patients in the placebo arm. Patients receiving 4mg/kg tocilizumab plus methotrexate experienced similar, though slightly lower results with 7.6% (p=0.0533) achieving DAS28 and 30.4% (p<0.0001) achieving ACR20.

Professor Paul Emery of Leeds Teaching Hospital Trust / Leeds University, UK, lead investigator in the trial, said: "Although anti-TNF therapies for RA are well-established, a substantial number of patients are inadequately controlled by these treatments, or become refractory to them. The results of this trial suggest that tocilizumab offers a much needed and effective option for such patients."

The RADIATE study was a randomised, double-blind study of 499 patients with moderate to severe RA. 12-18% of patients had 3 or more prior anti-TNF failures. A low proportion of the patients in the 8mg/kg tocilizumab group experienced serious adverse effects (6%) or serious infections (5%) during the trial. There was no difference in safety or tolerability based on prior anti-TNF treatment.


'/>"/>

Contact: Rory Berrie
eularpressoffice@uk.cohnwolfe.com
44-077-892-70392
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
2. 13 percent of women stop taking breast cancer drug because of side effects, U-M study finds
3. Ninety Percent of Polled Pain Care Professionals Express Fear of Regulation
4. Health Insurance Premiums Rise 6.1 Percent in 2007, Less Rapidly Than in Recent Years But Still Faster Than Wages and Inflation
5. Less than 3 percent of UK 11-year-olds take enough exercise
6. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
7. Hospitals See Infection Rates More Than Halved, Patient Stays Shortened by 27 Percent in New Study Announced by I-Flow
8. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
9. New research shows ACTOS is associated with a 38 percent lower risk of heart attack
10. New research shows ACTOS is associated with a 38 percent lower risk of heart attack
11. Sixty Percent of Americans Cannot Name Top Killers of Kids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... May 28, 2016 , ... In a part of the city where’s it’s easy to ... farm-to-table Kelowna restaurants is hoping to attract diners with a taste for real food. ... officially opened the doors to Cornerstone Grill, an urban casual restaurant focusing on dishes made ...
(Date:5/27/2016)... ... 27, 2016 , ... Two director-level employees of Horizon Blue Cross Blue Shield ... (TWIN) 2016 honorees. The award recognizes businesswomen who excel in their fields and ... of the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health and ...
(Date:5/27/2016)... ... , ... With over 60 percent of acute stroke survivors being left unable ... aid in the rehabilitation process has steadily increased. Ekso Bionics had been working to ... to stroke. , Ekso Bionics has now received clearance from the U.S. Food and ...
(Date:5/27/2016)... ... May 27, 2016 , ... In ... the many who are unaware of the plight of aphasia. In collaboration with ... the “Stroke Awareness” campaign. , The link between stroke and aphasia is relatively ...
(Date:5/27/2016)... ... 2016 , ... Aimed at nurses and employees in the health care world, ... in the nursing and health care industry. It also provides insight to the developing ... , As the nursing industry is coming out of one of the biggest ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... , May 24, 2016 ... beide primären Endpunkte und demonstriert ... in ‚ausgezeichneter plus guter , ...    ,      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ... heute neue positive Daten von der MORA-Studie der ...
(Date:5/24/2016)... CHRISTCHURCH, New Zealand , May 24, 2016 ... scanning and informatics solutions for the healthcare sector, has been ... the New Zealand Hi-Tech Awards 2016. Dr ... a fantastic acknowledgement for our team.  It,s really good to ... the burden healthcare internationally. Our products are used in 35 ...
(Date:5/24/2016)... INDIANAPOLIS , May 24, 2016  Joe Marziani has joined VMS BioMarketing as ... chief executive officer, today. In his new role, Marziani will lead the company,s business ... care professionals to improve outcomes. Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
Breaking Medicine Technology: